Sign in

    Maggie Boeye

    Research Analyst at William Blair

    Maggie Boeye is an Equity Research Associate at William Blair & Co. LLC, focusing on equity research within the finance and consumer services sectors since joining the firm in 2020. She has supported research coverage for companies including Adaptive Biotechnologies and QuidelOrtho, providing in-depth financial analysis and market insights that have contributed to high-quality client advisory and investment recommendations. Boeye began her professional career at William Blair after graduating from Mississippi State University in 2020 with an undergraduate degree, building her expertise within the firm’s research division. Her professional credentials include current registration with a SEC-registered broker/dealer, and she operates within the regulatory framework established by William Blair’s compliance with major securities authorities.

    Maggie Boeye's questions to SERA PROGNOSTICS (SERA) leadership

    Maggie Boeye's questions to SERA PROGNOSTICS (SERA) leadership • Q2 2025

    Question

    Maggie Boeye of William Blair inquired about the evolution of Sera's commercial strategy since the hiring of CCO Leigh Anderson and asked for an update on conversations with medical guideline bodies regarding the PRIME study data.

    Answer

    President and CEO Zhenya Lindgardt explained that the new CCO has sharpened the commercial message to emphasize how the PreTRM test augments care protocols, expanded the team with more experienced sales leaders, and upgraded capabilities by hiring a Head of Market Access. Regarding guidelines, Lindgardt noted that conversations with payers and opinion leaders about the PRIME study are incredibly rich and ongoing, with the breakthrough nature of the data prompting deep engagement and additional analysis, which has extended the publication timeline.

    Ask Fintool Equity Research AI

    Maggie Boeye's questions to VERACYTE (VCYT) leadership

    Maggie Boeye's questions to VERACYTE (VCYT) leadership • Q2 2025

    Question

    Maggie Boeye of William Blair & Company, on for Andrew Brackman, asked about the expected growth contribution from the Decipher metastatic launch in the second half of 2025 and into 2026, and also about the key milestones for driving Prosigna adoption post-launch.

    Answer

    CEO Marc Stapley and CCO John Leite noted early interest in the metastatic launch and a 'halo effect' on high-risk testing. CFO Rebecca Chambers specified the 2025 guidance does not assume a meaningful contribution from the metastatic launch itself, but it is a key long-term driver. For Prosigna, Stapley highlighted the mid-2026 launch and pivotal study results as key milestones, while Chambers added that securing reimbursement via a tech assessment is a critical step.

    Ask Fintool Equity Research AI

    Maggie Boeye's questions to QuidelOrtho (QDEL) leadership

    Maggie Boeye's questions to QuidelOrtho (QDEL) leadership • Q2 2025

    Question

    Maggie Boeye of William Blair, on behalf of Andrew Breckham, inquired about QuidelOrtho's respiratory expectations for the remainder of 2025, the rationale for the revised COVID-19 guidance, and the company's confidence in its narrowed growth forecast for China.

    Answer

    CFO Joseph Busky explained that the full-year COVID-19 revenue guidance was lowered to $70-$100 million due to rising positivity rates but lower disease severity, while flu guidance remains unchanged. CEO Brian Blaser added that the narrowed mid-single-digit growth forecast for China is supported by strong visibility and the company's differentiated clinical chemistry business, which is less exposed to volume-based procurement (VBP).

    Ask Fintool Equity Research AI

    Maggie Boeye's questions to EXAGEN (XGN) leadership

    Maggie Boeye's questions to EXAGEN (XGN) leadership • Q2 2025

    Question

    Asked for an update on the sales territory expansion plans for 2025 and beyond, and inquired about the levers for driving ASP growth aside from the recently launched markers.

    Answer

    The company is expanding its sales force empirically, expecting to grow from 40 territories at the start of the year to around 44-45 by year-end. For ASP growth, they see significant opportunity in improving collections on their base business through better payer coverage and appeals, aiming to close the large gap between their current ASP and the list price.

    Ask Fintool Equity Research AI

    Maggie Boeye's questions to EXAGEN (XGN) leadership • Q2 2025

    Question

    Maggie Boeye of William Blair inquired about the specifics of the sales territory expansion, including current numbers and year-end targets, and asked about the levers available to drive ASP growth beyond the impact of new markers.

    Answer

    CEO John Aballi detailed the sales force expansion from 40 to 42 territories in Q2, with a target of 44-45 by year-end, emphasizing an empirical, data-driven approach to adding reps. For ASP growth, he highlighted the significant gap between the current blended ASP ($428) and the clinical lab fee schedule rate ($1,299), citing ongoing appeals, payer engagement with Blues and national plans, and recent wins with TRICARE as key levers for continued improvement.

    Ask Fintool Equity Research AI